Adult Dosing
Ventricular arrhythmias
- Usual: 400 to 800 mg/day PO divided qid (CAPS) or divided bid (ECAPS)
- < 50 kg (110 lb) or patients with poor left ventricular function: 100 mg PO tid/qid (CAPS) or 200 mg PO bid (ECAPS)
- > 50 kg (110 lb): 150 mg PO qid (CAPS) or 300 mg PO bid (ECAPS)
- Max: 800 mg/day
Rapid Control of ventricular arrythmias
- < 50 kg: Initial loading dose of 200 mg CAPS PO, followed by 150 mg PO qid
- > 50 kg: Initial loading dose of 300 mg CAPS P,O followed by 150 mg PO qid
- Note: Loading dose not given if cardiomyopathy or cardiac decompensation
Pediatric Dosing
Ventricular arrhythmias
- < 1 yrs: 10-30 mg/kg/day PO divided qid
- 1-4 yrs: 10-20mg/kg/day PO divided qid
- 4-12 yrs: 10-15 mg/kg/day PO divided qid
- 12-18 yrs: 6-15 mg/kg/day PO divided qid
[Outline]
Renal Dose Adjustment (Based on CrCl)
- Immediate release
- > 40 mL/min: 100 mg PO q6 hrs
- 30- 40 mL/min: 100 mg PO q8 hrs
- 15-30 mL/min: 100 mg PO q12 hrs
- < 15 mL/min: 100 mg PO qd
- Extended release
- > 40 mL/min: 200 mg PO q12 hrs
- < 40 mL/min: Avoid ER form, use IR form
Hepatic Dose Adjustment
- Immediate release: 400 mg/day PO in divided doses as 100 mg qid
- Extended release: 400 mg/day PO in divided doses as 200 mg bid
- Treatment of patients with ventricular premature contractions or other non-life threatening arrhythmia should be avoided
- If HTN occurs or congestive heart failur worsens, disopyramide should be discontinued and, if required, restarted at a lower dosage only after adequate cardiac compensation has been established
- Do not use in patients with glaucoma, myasthenia gravis, or urinary retention unless adequate overriding measures are taken due to significant anticholinergic effects
- Reduce dose if first degree heart block develops in a patient receiving disopyramide
- Monitor for hypotension, hypoglycaemia, ventricular tachycardia, ventricular fibrillation or torsade de pointes (discontinue if occur)
Cautions: Use cautiously in
- Hepatic or renal insufficiency (dosage reduction recommended)
- CHF or left ventricular dysfunction (dosage reduction recommended)
- Prostatic enlargement
- Myasthenia gravis
- Glaucoma
- Geriatric population (may induce heart failure)
- Sick Sinus Syndrome / Wolff-Parkinson-White Syndrome / Bundle branch block
- Urinary retention, including BPH
Pregnancy Category:C
Breastfeeding: Disopyramide is secreted in breast milk. An exclusively breastfed infant would receive 2.5-3% of the maternal weight-adjusted dosage (if mother receiving 500 mg/day). This drug should be used with caution based upon LactMed database (available at http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT last accessed 7 January 2011). Manufacturer recommends discontinuation of breastfeeding, or postponing of treatment (taking into account the importance of the drug to the mother).
Pricing data from www.DrugStore.com in U.S.A.
- Norpace 100 MG CAPS [Bottle] (PFIZER U.S.)
90 mg = $163.48
270 mg = $469.75 - Norpace 150 MG CAPS [Bottle] (PFIZER U.S.)
30 mg = $65.39
90 mg = $170.01 - Norpace CR 100 MG CP12 [Bottle] (PFIZER U.S.)
60 mg = $129.99
180 mg = $363.97 - Norpace CR 150 MG CP12 [Bottle] (PFIZER U.S.)
60 mg = $153.67
180 mg = $439.23
Warning: This pricing information is subject to change at the sole discretion of DS Pharmacy. For the most current and up-to-date pricing information, please visit drugstore.com.
